Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Michael Muenzberg"'
Publikováno v:
Acta Ophthalmologica. 100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::878d2b88c64572286523d63d54e47607
https://doi.org/10.1111/j.1755-3768.2022.0018
https://doi.org/10.1111/j.1755-3768.2022.0018
Autor:
Matthew Turner, Carsten Bokemeyer, Ivo Abraham, Heinz Ludwig, Mario Boccadoro, Pere Gascón, Michael Muenzberg, Kris Denhaerynck, Matti Aapro, Karen MacDonald
Publikováno v:
Cancer Research. 75:P5-15
Introduction: MONITOR-GCSF is a European prospective observational study of practice patterns and outcomes of patients treated with Sandoz' filgrastim (EP-2006) in the prophylaxis of chemotherapy-induced febrile neutropenia (CIN/FN). Objectives: To d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e11ec48ec807829c77dc70d67d80686
https://doi.org/10.1158/1538-7445.sabcs14-p5-15-19
https://doi.org/10.1158/1538-7445.sabcs14-p5-15-19
Autor:
Matthew Turner, Maria Sofia Rosati, Helen Barker, Karl Verpoort, Hans Tesch, Samir G. Agrawal, Nello Salesi, Nils Wilking, Pere Gascón, Michael Muenzberg
Publikováno v:
Supportive Care in Cancer
Biosimilars are similar, but non-identical, versions of existing biological drugs for which patents have expired. Despite the rigorous approval process for biosimilars, concerns have been expressed about the efficacy and safety of these products in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88bb24ef6019ca5e2de93c54e09727cc
https://doi.org/10.1007/s00520-013-1911-7
https://doi.org/10.1007/s00520-013-1911-7
Autor:
Markus Zabransky, Yannic B. Pannatier Schuetz, Fritz Sörgel, Patricia Gravel, Richard Stanhope, Michael Muenzberg
Publikováno v:
The Journal of Clinical Pharmacology. 50:1339-1348
This article discusses the bioequivalence of Omnitrope (Sandoz's rhGH biosimilar) and Genotropin (reference rhGH product), assessed in the first 2 clinical phase 1 studies conducted during the development of Omnitrope. Both of these phase 1 studies w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b28e16aa24952d223aec4a2ccf91ac3
https://doi.org/10.1177/0091270009359005
https://doi.org/10.1177/0091270009359005
Autor:
Michael Muenzberg, Matti Aapro, Robert Dunlop, Ivo Abraham, Joanna Van Erps, Karen MacDonald, Pierre Soubeyran, Hans Warrinnier, Matthew Turner
Publikováno v:
Critical Reviews in Oncology/Hematology. 65:32-42
The 2006 EORTC guidelines for erythropoietic proteins in cancer-related anemia provide the most up-to-date assessment of the evidence base. Considering general concerns in medicine about clinicians' adoption of evidence-based guidelines, it is critic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ea8bb2c39007020bc9f4d0321decd3f
https://doi.org/10.1016/j.critrevonc.2007.05.002
https://doi.org/10.1016/j.critrevonc.2007.05.002
Autor:
Dirk Samland, Michael Muenzberg, Martin Löffler, Micol Panozzo, Patricia Gravel, Simone Maier
Publikováno v:
Advances in therapy. 30(3)
This study set out to examine the efficacy and tolerability of two innovative implant forms of leuprorelin acetate in men with advanced hormone-dependent prostate cancer in everyday clinical practice. Data were collected from 818 patients (from 273 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb647820669176650e9565862ecefe0
https://pubmed.ncbi.nlm.nih.gov/23460040
https://pubmed.ncbi.nlm.nih.gov/23460040
Publikováno v:
Expert opinion on biological therapy. 12(11)
Introduction: The approval of several biosimilars in the past years has prompted discussion on potential safety risks associated with switching to and from these products. It has been suggested that switching may lead to safety concerns. However, dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5291c6a311b4a379ec4b0e6cee98fa
https://pubmed.ncbi.nlm.nih.gov/22849511
https://pubmed.ncbi.nlm.nih.gov/22849511
Autor:
Ivo Abraham, Pere Gascón, Michael Muenzberg, Karen MacDonald, M. Boccadoro, Matthew Turner, Nadia Rosencher, Matti Aapro, Heinz Ludwig
Publikováno v:
Critical reviews in oncology/hematology. 77(3)
The MONITOR-GCSF study is an international, prospective, observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the use of biosimilar filgrastim in the prophylaxis of febrile neutropenia in chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00cfc82e4707b05403bc5a8e17da2397
https://pubmed.ncbi.nlm.nih.gov/21377576
https://pubmed.ncbi.nlm.nih.gov/21377576
Autor:
S. Balser, A. Makhson, Pere Gascón, S. Einmahl, Uwe Fuhr, Michael Muenzberg, Martina Kinzig-Schippers, Fritz Sörgel
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 21(7)
Background Zarzio®, a new recombinant human granulocyte colony-stimulating factor (filgrastim), was evaluated in healthy volunteers and neutropenic patients in phase I and III studies. Patients and methods Healthy volunteers in randomized, two-perio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8c6622a98878a9e5a1f9e6f61e4c59
https://pubmed.ncbi.nlm.nih.gov/20019087
https://pubmed.ncbi.nlm.nih.gov/20019087
Autor:
Ivo Abraham, Nadia Rosencher, Karen MacDonald, Pere Gascón, Michael Muenzberg, Matti Aapro, Heinz Ludwig, Christopher S. Lee, Matthew Turner, MinKyoung Song
Publikováno v:
Critical reviews in oncology/hematology. 77(3)
The MONITOR-GCSF study is an international, prospective, observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the use of Zarzio(®) in the prophylaxis of febrile neutropenia in chemotherapy-tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac2389cd74322cb19aaf26de694c1f55
https://pubmed.ncbi.nlm.nih.gov/20189821
https://pubmed.ncbi.nlm.nih.gov/20189821